Effectiveness of the vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty to fifty-nine years
Revista Espanola de Salud Publica
; 96(e202209060es), 2022.
Article
in Spanish
| GIM | ID: covidwho-2317350
ABSTRACT
In this paper we compared brand-specific COVID-19 vaccine effectiveness (VE) during August 2021 in persons born 1962-1971 and vaccinated during June. For SARS-CoV-2 symptomatic infection, protection was lower for Janssen (56%;CI95% 53-59) or AstraZeneca [Vaxzevria] (68%;CI95% 65-70), compared to Pfizer-BioNTech [Comirnaty] (78%;CI95% 77-78), AstraZeneca/Pfizer (86%;CI95% 80-90) or Moderna [Spikevax] (89%;CI95% 88-90). VE against hospitalization was ranged 86% for Janssen to 97%-98% for other vaccines.
brand name products; coronavirus disease 2019; disease prevention; efficacy; elderly; elderly patients; health protection; hospital admission; human diseases; immunity; immunization; vaccination; vaccines; viral diseases; immune sensitization; man; Severe acute respiratory syndrome coronavirus 2; Spain; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; European Union Countries; high income countries; Mediterranean Region; OECD Countries; Southern Europe; Europe; very high Human Development Index countries; aged; elderly people; older adults; senior citizens; SARS-CoV-2; viral infections
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Experimental Studies
Topics:
Vaccines
Language:
Spanish
Journal:
Revista Espanola de Salud Publica
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS